MONITORING GLUCOCORTICOID THERAPY - A PHARMACOKINETIC APPROACH

被引:85
作者
HILL, MR
SZEFLER, SJ
BALL, BD
BARTOSZEK, M
BRENNER, AM
机构
[1] NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO
[2] UNIV COLORADO,HLTH SCI CTR,SCH PHARM,DEPT PHARMACOL,DENVER,CO 80262
[3] UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT PEDIAT,DENVER,CO 80262
关键词
D O I
10.1038/clpt.1990.167
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although glucocorticoid therapy is essential for the treatment of severe inflammatory disorders, there is no systematic approach to patient variables that may affect availability of a steroid dose. After the development of a data base of pharmacokinetic parameters, we examined glucocorticoid pharmacokinetics in 54 patients between 2 and 70 years of age using 70 pharmacokinetic studies after administration of intravenous methylprednisolone (n = 25), oral methylprednisolone (n = 15), intravenous prednisolone (n = 18), and oral prednisone (n = 12). Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [±LSD] 380 ± 100 ml/min/1.73 m2) without an identifiable cause. Incomplete absorption of methylprednisolone and prednisone was observed in three patients and one patient, respectively. Evaluation of glucocorticoid pharmacokinetics in children aged 1 year 8 months to 18 years demonstrated a significant inverse correlation (r = 0.88; p < 0.001) between prednisolone clearance and age. It is therefore important to consider age in the interpretation of pharmacokinetic data. To simplify measurement of prednisolone clearance, a single-dose single-point method was developed. This was based on a highly significant relationship between the 6-hour postdose prednisolone concentration and prednisolone clearance (log prednisolone clearance = 2.66 + [6-hour postdose concentration] [-0.00167]; r2 = 0.96; p < 0.0001). Evaluation of glucocorticoid pharmacokinetics in the clinical setting can be used to identify abnormalities in absorption, elimination, and patient compliance. This technique can be used to individualize glucocorticoid dosing regimens. © 1990.
引用
收藏
页码:390 / 398
页数:9
相关论文
共 32 条
[1]   PREDNISOLONE AND METHYLPREDNISOLONE KINETICS IN CHILDREN RECEIVING ANTICONVULSANT THERAPY [J].
BARTOSZEK, M ;
BRENNER, AM ;
SZEFLER, SJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) :424-432
[2]   GLUCOCORTICOID RECEPTORS IN LEUKEMIA AND LYMPHOMA [J].
BLOOMFIELD, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (04) :323-328
[3]   PREDNISOLONE DISPOSITION AND PROTEIN-BINDING IN ORAL-CONTRACEPTIVE USERS [J].
BOEKENOOGEN, SJ ;
SZEFLER, SJ ;
JUSKO, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (04) :702-709
[4]   RECEPTOR-MEDIATED PHARMACODYNAMICS OF PREDNISOLONE IN THE RAT [J].
BOUDINOT, FD ;
DAMBROSIO, R ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1986, 14 (05) :469-493
[5]  
BRAUDE AC, 1983, LANCET, V2, P995
[6]   INTERACTION OF RIFAMPIN AND GLUCOCORTICOIDS - ADVERSE EFFECT ON RENAL-ALLOGRAFT FUNCTION [J].
BUFFINGTON, GA ;
DOMINGUEZ, JH ;
PIERING, WF ;
HEBERT, LA ;
KAUFFMAN, HM ;
LEMANN, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 236 (17) :1958-1960
[7]   ANALYSIS OF CORTISOL, METHYLPREDNISOLONE, AND METHYLPREDNISOLONE HEMISUCCINATE - ABSENCE OF EFFECTS OF TROLEANDOMYCIN ON ESTER HYDROLYSIS [J].
EBLING, WF ;
SZEFLER, SJ ;
JUSKO, WJ .
JOURNAL OF CHROMATOGRAPHY, 1984, 305 (02) :271-280
[8]   METHYLPREDNISOLONE AND TROLEANDOMYCIN IN TREATMENT OF STEROID-DEPENDENT ASTHMATIC-CHILDREN [J].
EITCHES, RW ;
RACHELEFSKY, GS ;
KATZ, RM ;
MENDOZA, GR ;
SIEGEL, SC .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1985, 139 (03) :264-268
[9]   GLUCOCORTICOSTEROID THERAPY - MECHANISMS OF ACTION AND CLINICAL CONSIDERATIONS [J].
FAUCI, AS ;
DALE, DC ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (03) :304-315
[10]   BIOAVAILABILITY ASSESSMENT OF A LIQUID PREDNISONE PREPARATION [J].
GEORGITIS, JW ;
FLESHER, KA ;
SZEFLER, SJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1982, 70 (04) :243-247